217 related articles for article (PubMed ID: 32253579)
1. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis.
Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; St-Hilaire PA; Tian Z; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
World J Urol; 2021 Feb; 39(2):461-472. PubMed ID: 32253579
[TBL] [Abstract][Full Text] [Related]
2. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma.
Huang J; Huang D; Yan J; Chen T; Gao Y; Xu D; Na R
Cancer Med; 2020 Dec; 9(24):9409-9418. PubMed ID: 33141518
[TBL] [Abstract][Full Text] [Related]
4. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
[TBL] [Abstract][Full Text] [Related]
5. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
6. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
Dudani S; de Velasco G; Wells JC; Gan CL; Donskov F; Porta C; Fraccon A; Pasini F; Lee JL; Hansen A; Bjarnason GA; Beuselinck B; Pal SK; Yuasa T; Kroeger N; Kanesvaran R; Reaume MN; Canil C; Choueiri TK; Heng DYC
JAMA Netw Open; 2021 Jan; 4(1):e2021869. PubMed ID: 33475752
[TBL] [Abstract][Full Text] [Related]
8. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
10. [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].
Waalkes S; Roos FC; Eggers H; Schumacher S; Janssen M; Wegener G; Thüroff JW; Hofmann R; Schrader M; Kuczyk MA; Schrader AJ;
Urologe A; 2011 Sep; 50(9):1125-9. PubMed ID: 21845424
[TBL] [Abstract][Full Text] [Related]
11. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
[TBL] [Abstract][Full Text] [Related]
12. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
14. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
[TBL] [Abstract][Full Text] [Related]
15. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.
Kim SH; Kim JK; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
Oncotarget; 2017 Jul; 8(30):49615-49624. PubMed ID: 28548948
[TBL] [Abstract][Full Text] [Related]
16. Incidence and long-term prognosis of papillary renal cell carcinoma.
Schrader AJ; Rauer-Bruening S; Olbert PJ; Hegele A; Rustemeier J; Timmesfeld N; Varga Z; Hofmann R
J Cancer Res Clin Oncol; 2009 Jun; 135(6):799-805. PubMed ID: 19023595
[TBL] [Abstract][Full Text] [Related]
17. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
18. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis.
Yamashita S; Ioritani N; Oikawa K; Aizawa M; Endoh M; Arai Y
Int J Urol; 2007 Aug; 14(8):679-83. PubMed ID: 17681054
[TBL] [Abstract][Full Text] [Related]
19. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
